# A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

> **NCT02358031** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 882 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer
- Metastatic Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** 5-FU
- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT02358031
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-19
- **Primary completion:** 2019-02-25
- **Final completion:** 2023-07-19
- **Target enrollment:** 882 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02358031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02358031, "A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02358031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*